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Review
During the past 30 years, many environmental 
health concerns linked with early-life exposures 
to environmental agents have centered on dis-
eases that are increasing in prevalence in many 
countries, are often chronic in nature, and can 
significantly affect both health care needs and 
quality of life. Among those diseases and con-
ditions are childhood asthma and other aller-
gic diseases, various autoimmune conditions 
(e.g., type 1 diabetes, arthritis, autoimmune 
thyroiditis, celiac disease, multiple sclerosis), 
neurological tissue disorders (e.g., autism, 
schizophrenia, Parkinson’s disease, Alzheimer’s 
disease), and metabolic and cardiovascular dis-
orders (e.g., childhood obesity, cardiac disease, 
atherosclerosis). Most of these diseases have 
at least three features in common: early-life 
exposures to environmental risk factors (i.e., 
chemical agents or pathogens) are thought to 
be important in disease risk; immune-inflam-
matory insult or dysfunction is evident; and 
the disease itself and/or early biomarkers of 
later-life disease are prominent in previously 
exposed children.
Childhood immune-based diseases with 
environmental risk factors can affect as much 
as 25% of the pediatric population in some 
developed countries (Dietert and Zelikoff 
2009). Although this impact of environmen-
tally influenced, immune-based disease is of 
significant concern, it does not reflect the full 
extent of the problem between environmental 
risk factors and immune system health. Among 
subpopulations of children, significant illnesses 
such as asthma and type 1 diabetes are not 
only the end result of environmental exposures 
interacting with genetic background; they are 
the entryway into even larger environmen-
tally associated health concerns. This is because 
asthma, type 1 diabetes, and many other ill-
nesses that are prominent in children are inter-
linked to an elevated risk of other diseases via a 
superstructure that has been termed a “pattern” 
of disease (Dietert and Zelikoff 2010).
At the heart of a disease pattern is the first-
onset disease or condition. The earliest disease 
has been termed the “entryway” disease for a 
specific pattern (Dietert and Zelikoff 2010). 
Once that disease arises, elevated health risks 
for comorbidities are often triggered in the 
diagnosed pediatric population. These sec-
ondary diseases may occur during childhood 
or later in life. Although patterns of diseases 
are most often connected via underlying bio-
logical mechanisms, in some cases a predomi-
nant course of medical treatment may have 
the potential to contribute to an elevated risk 
for certain secondary conditions.
The contributions of immune dysfunction 
and immune-based childhood illnesses and 
diseases to larger “patterns” of disease are only 
beginning to be fully appreciated. This latter 
point is particularly significant when environ-
mental risk factors are viewed across a lifetime. 
If a diagnosis of asthma in childhood implies 
elevated health risks for several other serious 
adult-onset diseases, then there is an added 
value in preventing childhood asthma if such 
action might reduce the risk of additional 
health conditions later in life. In fact, effec-
tive immune homeostasis is a crucial aspect of 
health across all age groups. Even in the latest 
stages of life, disruption of immune homeo-
stasis appears to differentiate dementia from 
normal cognitive function (Katsel et al. 2009).
In the present review, we illustrate several 
disease patterns where immune and inflam-
matory dysfunction appear to be most impor-
tant. We show how the intersection of disease 
patterns can shed light on potential multiple 
routes for developing a single disease or con-
dition. Finally, we describe how a pattern of 
diseases can be substituted for the traditional 
single-disease focus to optimize integrative 
environmental health protection strategies.
Underestimating the Role of 
Environmentally Influenced 
Immune Dysfunction in Disease
Historically, the immune system has been 
viewed first and foremost in the context of 
primary immune organs (e.g., thymus) and 
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secondary sites of acquired immune responses 
(e.g., spleen and lymph nodes). This has been 
strengthened by the focus on host defense 
against external assaults (often microbiologi-
cal) that were critical in defining an impor-
tant role of the immune system. Additional 
events involving immune cells in other tissues 
and organs were largely defined by the nature 
and physiological function of that tissue (e.g., 
cardio vascular, neurological, reproductive, 
endocrine, hepatic, respiratory). This resulted 
in many immune-based diseases being catego-
rized and treated by medical specialists based 
on tissue location and biological function 
rather than by the underlying cause of the dis-
ease (Dietert, in press). As will be discussed in 
the context of breaking or disrupting a pattern 
of disease, the focus on disease location (by 
system) rather than on the underlying cause 
may actually hamper efforts to break the cycle 
of diseases influenced by environmental risk 
factors across a lifetime.
Viewing the immune system in a manner 
restricted to primary and secondary lymphoid 
organs overlooks additional immune functions 
that are equally important for health and well-
being. Early in life, immune cells are distribu-
ted to virtually every tissue and organ of the 
body, where they serve as sentries for organ 
integrity and homeostatic regulators of the 
tissue’s physiological function. Most of these 
cells either are macrophage-lineage related or 
represent highly specialized lymphocyte pop-
ulations (e.g., intraepithelial lymphocytes). 
In fact, in organs critical for metabolism and 
growth (e.g., liver), the functional status of the 
majority of the cell populations (hepatocytes) 
can be significantly influenced, if not largely 
dictated, by the minority resident immune 
cell population: the Kupffer cells (Neyrinck 
et al. 2009; Usynin and Panin 2008; Wang 
et al. 2009).
Macrophage-like cells exhibit unique 
pheno types and differential environmental 
sensitivity depending on their location in 
the body. As a result, Kupffer cells in liver, 
Langerhans cells and keratinocytes in skin, 
alveolar macrophages in lung, microglia and 
astrocytes in brain, foam cells of atherosclerotic 
plaques, preadipocytes in adipose tissue, osteo-
clasts in bone, and testicular macrophages, 
although all related in lineage, exhibit sig-
nificant differences in terms of either specific 
leukocyte function or environmental sensitiv-
ity. Dysfunction among these resident macro-
phage populations can cause diseases in situ 
that, as mentioned, are usually labeled and 
medically treated based on the involved tissue. 
But, if the actual environmental exposures 
involve earlier-in-life induction of immune 
dysfunction, tissue-specialized treatments 
may only address immune-mediated loss of 
that tissue’s physiological function and may 
not correct the underlying immune dysfunc-
tion. The danger across a lifetime is that the 
 unaddressed dysfunction may elevate addi-
tional health risks associated with aging and 
exposure to additional environmental triggers. 
Not surprisingly, the immune cells in question 
(i.e., macrophages) are particularly susceptible 
to early-life modulation and imprinting by 
environmental risk factors in ways that can 
affect even basic growth parameters across a 
life course (DeWitt and Dietert 2010).
Examples of diseases and conditions that 
have an established immune dysfunction as 
a basis but that are often categorized by tis-
sue or organ pathology are atherosclerosis 
(cardiovascular), asthma (respiratory), celiac 
disease (gastrointestinal), psoriasis (dermal), 
and multiple sclerosis (neurological) (Dietert, 
in press). For other illnesses where immune 
dysfunction or immune insult is suspected as 
a possible pathway to disease, recognition of 
likely immune involvement is even less appar-
ent (e.g., neurobehavioral, neurodeficit, and 
fatigue disorders).
Environmental Disruption of the 
Developing Immune System
The developing immune system is highly sus-
ceptible to modification and disruption by 
environmental influences and is at significantly 
greater risk than the fully matured immune 
system of an adult (Luebke et al. 2006). The 
health risks and concerns for the developing 
immune system are real, and specific examples 
of human vulnerability are known (Selgrade 
2007). In part, the elevated risk of develop-
mental immune dysfunction is based on the 
fact that numerous unique immune matu-
rational events are programmed into specific 
windows of prenatal and neonatal develop-
ment. These maturational events represent 
building blocks upon which subsequent 
changes in the immune system are built.
The period in which each unique immune 
maturation event occurs is known as a “critical 
window of immune vulnerability” (Dietert 
et al. 2000). For example, during thymocyte 
maturation in the thymus, negative selec-
tion occurs to eliminate thymocytes that have 
autoreactive capabilities and that are likely 
to promote later-life autoimmunity. Specific 
environmental agents such as lead, cortico-
steroids, and halogenated hydrocarbons are 
known to disrupt one or more specific devel-
opmental windows of immune vulnerability. 
Critical windows for the developing immune 
system were originally described a decade ago 
(Dietert et al. 2000; Landreth 2002) and were 
later updated to include additional events sus-
ceptible to disruption by environmental risk 
factors (Dietert and Piepenbrink 2006). More 
recently, the critical windows were subdivided 
into systemic versus local events that were tai-
lored for disease-specific health risks (Dietert 
and Dietert 2008). Later in this review, we 
extend this concept to suggest potential critical 
windows of immune development for a proto-
typic pattern of diseases and conditions known 
as metabolic syndrome.
Adverse Outcomes of 
Developmental Immunotoxicity
Developmental immunotoxicity (DIT) can 
be defined as adverse effects on the immune 
system resulting from exposure to environmen-
tal risk factors, including chemical, biological, 
physical, or physiological factors, before adult-
hood (Luster et al., in press). With most pat-
terns of disease, it is exposure to environmental 
risk factors prior to adulthood that is of greatest 
concern. Even for diseases with adult or geriat-
ric onset, the under lying disease mechanisms 
are usually established much earlier in life, and 
biomarkers of increased risk of future disease 
usually appear well in advance of disease onset 
(Kwiterovich 2008). This is certainly true for 
diseases with immune linkages.
Adverse outcomes of DIT can take many 
forms as shown in Figure 1. These include not 
only immunosuppression, but also increased 
risk of allergic and autoimmune diseases, 
inflammatory and metabolic dysfunction, 
and health problems associated with immune-
 inflicted damage of tissues and organs (Dietert 
2009b). Ironically, the historic and current 
focus of both DIT and adult immunotoxicity 
testing is on immunosuppression and poten-
tial allergenicity of test compounds (Dietert 
and DeWitt 2010). Although detection of 
immune suppression is useful, it is the remain-
ing adverse immune outcomes (Figure 1, 
box) that appear to be more important public 
health risks when one considers prevalence 
of chronic disease and significant patterns of 
immune-based disease (Dietert and Zelikoff 
2009). One goal is to better align immuno-
toxicity testing with prioritized health risk 
reduction. As will become evident in the sub-
sequent discussion of patterns of disease, much 
Figure 1. The adverse outcomes of developmen-
tal and adult immunotoxicity. The detection of 
immune suppression is useful, but it is the remain-
ing adverse immune outcomes (boxed) that appear 
to be the more important public health risks when 
one considers prevalence of chronic disease and 
significant patterns of immune-based disease.
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of the concern for immune-based chronic dis-
ease occurs less with issues of immunosuppres-
sion (or a single chemical’s allergenicity) than 
with the other types of adverse outcomes of 
immunotoxicity (i.e., predisposition for auto-
immunity, allergy, inflammatory disease, and 
inflammation-related tissue damage).
One of the most significant public health 
concerns of today is influenza. Risk of com-
plications and even death from influenza are 
among the major historic and present-day con-
cerns. Given that influenza virus infection is 
the initiator of the disease, one might easily 
assume that immunosuppression is the great-
est DIT risk relative to later-life influenza. But 
this assumption is less obvious than it might 
seem. Inappropriate immune responses are at 
least as important in determining life-short-
ening or life-threatening complications from 
influenza as are insufficient levels of immune 
responses (Baskin et al. 2009; Cillóniz, et al. 
2009; Hussell and Cavanagh 2009; Lin et al. 
2008). Problematic immune and inflammatory 
responses to the initial viral infection in the air-
ways can result in secondary bacterial infections 
(Rothberg et al. 2008) and severe damage to 
epithelial layers (Hussell and Cavanagh 2009), 
which can increase the risk of mortality.
Additionally, exposure to infectious agents 
like the influenza virus can trigger a wide range 
of diseases when preexisting and underlying 
immune dysfunctions are present (Dietert 
2009c). The nature of the disease outcome 
appears to depend upon the nature of the 
underlying immune dysfunction and the type 
of infectious agent encountered. This type of 
relationship has been suggested in the case of 
sudden infant death syndrome (Blood-Siegfried 
et al. 2002, 2008). Additionally, infectious 
agent triggers of immune-dysfunction–based 
disease are thought to play a role in specific 
allergic, autoimmune, and inflammatory dis-
eases as well as in some forms of childhood 
leukemia (Dietert 2009a; Greaves 2006).
Early-life exposure to environmental risk 
factors can significantly affect not only whether 
a childhood or adult immune response is ade-
quate, but also whether an immune response is 
misdirected (i.e., prolonged, not long enough, 
or skewed toward inappropriate response 
types). Hogaboam et al. (2008) demonstrated 
that in mice a single in utero exposure to 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
resulted in production of a hyper- or mis-
directed inflammatory response in the lungs of 
the offspring that increased lung damage and 
mortality after later infection with influenza. 
The potential for inappropriate inflammation 
already existed in these mice as a result of pre-
natal exposure to TCDD but was not revealed 
or apparent until the animals were faced with 
a viral challenge later in life. Without proper 
and relevant challenges among DIT testing 
paradigms, relationships between early-life 
exposures and later-life responses to other 
environmental risk factors may be missed.
The questions of how, when, and in 
what way DIT testing should be conducted 
relates directly to current public health con-
cerns in humans (Dietert and DeWitt 2010). 
Employing the full range of DIT testing rele-
vant to our most significant public health 
concerns would increase the likelihood of 
reducing environmentally influenced health 
risks and associated disease prevalence for pri-
ority diseases, regardless of whether they are 
considered individually or as lifelong patterns 
of disease. For this reason, we support required 
DIT safety testing of drugs and chemicals.
The Importance of Disease 
Patterns
Historically, environmentally influenced 
health risk prioritization, funding, research, 
and public health policies have been driven 
by a focus on individual diseases and condi-
tions. Individual diseases usually take priority 
for public attention, investigation, and action. 
For this reason, diseases and conditions with 
documented environmental influences such 
as arthritis; asthma and allergies; breast, lung, 
and prostate cancer; heart disease; hearing loss; 
obesity; otitis media; periodontal disease; sleep 
disorders; and thyroid disorders are impor-
tant categories of our public health effort. 
The benefit of the single-disease approach is 
that the research path from scientific under-
standing to public health and policy changes 
is reasonably direct and relatively transpar-
ent. But the downside is that the immedi-
ate return on this coordinated effort is likely 
restricted to the single disease in question, 
the known environmental risk factors that 
can be most readily addressed for that disease, 
and health management that is restricted to a 
single  disease in isolation.
The potential problem with this historic 
approach is that preventing and managing 
environmentally influenced diseases can 
become little more than a series of uncoor-
dinated piecemeal opportunities driven by a 
single-disease mantra. But diseases rarely occur 
in isolation. Instead, they exist as part of a 
pattern or superstructure of health risks across 
a lifetime (Dietert and Zelikoff 2010). With 
recent increased use of information contained 
in large medical databases, it is apparent that 
disease risk is organized into complex webs 
or patterns. The conditions that give rise to a 
pediatric disease often foretell the predomi-
nant health risks that will be faced in each 
subsequent decade of life (Dietert and Zelikoff 
2009). With this in mind, the debate then 
becomes whether it is better to focus on sin-
gle diseases or on landscapes (i.e., the webs) 
defined by multiple diseases and intercon-
nected health risks. Therefore, it is worthwhile 
to consider the cost-effectiveness of protecting 
against single diseases versus patterns of dis-
eases. In the following sections, we consider 
this point using recent, relevant examples.
Metabolic Syndrome as a 
Pattern of Environmentally 
Influenced Disease
Metabolic syndrome is by definition a pat-
tern of conditions and elevated disease risks 
(Grundy 2008). It is also a syndrome that 
features one type of immune dysfunction, 
excessive and misdirected immune inflam-
mation, among its major characteristics. In 
fact, we would argue that the same approach 
that has led to heightened awareness, utility, 
and effectiveness of addressing the cluster of 
significant health risks connected to the meta-
bolic syndrome pattern should be applied to 
a wider range of diseases and conditions. This 
approach is precisely what should be extended 
to other patterns of disease and used as the 
rule for reducing environmental health risks 
rather than as a novel exception.
Although some definitions differ slightly 
for what constitutes metabolic syndrome, it is 
generally thought of as the coexistence of three 
or more of the following five criteria: insulin 
resistance, high blood pressure, obesity, ele-
vated triglycerides, and reduced high-density 
lipoprotein cholesterol (Grundy et al. 2004). 
Additionally, inflammatory dysfunction is a 
hallmark of metabolic syndrome (Fessler et al. 
2009; Hevener et al., in press; Solomon et al. 
2009; Suzuki et al. 2008). Indeed, under-
lying excessive and misdirected inflammation 
is thought to promote many of the diseases 
associated with metabolic syndrome (Milner 
et al. 2009; Rizvi 2009). The presence of met-
abolic syndrome is associated with an elevated 
risk of diabetes (Duvnjak and Duvnjak 2009), 
hepatic steatosis (Watanabe et al. 2008), kid-
ney disease (Fakhrzadeh et al. 2009), stroke 
(Niwa et al. 2010), heart disease (Noda et al. 
2009), and other cardiovascular morbidi-
ties, such as atherosclerosis (Kawamoto et al. 
2007). Unlike other patterns of disease where 
immune dysfunction is clearly the underlying 
cause of the pattern, determining the precise 
relationship between metabolic syndrome and 
immune-inflammatory dysfunction requires 
additional study. The dysfunction here may 
be either causative of other metabolic syn-
drome conditions or, alternatively, associated 
with other metabolic syndrome conditions via 
some common mechanism.
Metabolic syndrome as a prototype for 
pattern-based health risk reduction. Figure 2 
illustrates the health risk pattern connected to 
metabolic syndrome, beginning with environ-
mental risk factors and ending with elevated 
risk for several chronic diseases. As is dis-
cussed for subsequent patterns using pediatric 
immune-dysfunction–based entryway diseases, 
there are two major opportunities to reduce 
Dietert et al.
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the impact of environmental risk factors on 
pattern-associated health risks and essentially 
prevent or disrupt the pattern (Figure 2). 
The first involves preventing the underlying 
cause through identification and avoidance of 
environmental risk factors that contribute to 
metabolic syndrome. The second opportunity 
involves intervening in the progression of the 
disease pattern (using medical treatment to 
address the overall pattern rather than just the 
initial presenting condition or disease). This 
would mean managing childhood or adult 
metabolic syndrome to minimize the risk of 
the associated diseases such as atherosclerosis, 
type 2 diabetes, and heart disease. As we will 
show with other immune-dysfunction–based 
patterns of disease, those same two opportuni-
ties exist once the pattern has been identified 
and can be used for health risk reduction.
Inflammatory dysfunction and metabolic 
syndrome. Several important points can be 
made about the metabolic syndrome pat-
tern and immune dysfunction. Both can be 
established early in life, and biomarkers for 
metabolic syndrome and inflammatory dys-
function can usually be detected in children 
(Huang et al. 2009). However, onset of the 
actual metabolic syndrome conditions and 
associated comorbidities, including inflamma-
tion-mediated diseases (e.g., atherosclerosis), 
may not occur until adulthood. Recognition 
of the connection between immune dysfunc-
tion, low-level chronic inflammation, and 
metabolic syndrome appears to be growing 
(DeWitt and Dietert 2010). In fact, obesity 
itself is sometimes viewed as a chronic, low-
grade inflammatory state (Lacasa et al. 2007). 
For this reason, the functional status of both 
T-lymphocyte populations and macrophages 
in the child is an important consideration 
relative to obesity (Nishimura et al. 2009; 
Schaffler and Scholmerich 2010). Figure 3 
shows the windows of immune maturation 
that are likely to be most relevant to metabolic 
syndrome. It also illustrates categories of envi-
ronmental risk factors that appear to influence 
the risk of metabolic syndrome (DeWitt and 
Dietert 2010; Dietert and Dietert 2010).
The probable relationship between immune 
status and metabolic syndrome is related to the 
suggestion that adipose tissue functions much 
like an immune organ. This is not a surprising 
concept because a variety of specific tissues and 
organs (i.e., brain, liver, gut, lung, and skin) 
have been increasingly recognized as having 
their own specialized microimmune systems, 
which are critical in determining both pediatric 
and adult function and dysfunction (Barone 
et al. 2009; Bienenstock and McDermott 
2005; Carpentier and Palmer 2009; Heier 
et al. 2008; Nemeth et al. 2009; Zaba et al. 
2009). Additionally, the close interaction 
between preadipocytes, adipocytes, and macro-
phages (resident and infiltrating), the capacity 
of resident adipose cells to produce immune 
cyto kines, and the capacity of preadipocytes 
to convert into macrophage-like cells (Isakson 
et al. 2009; Schaffler et al. 2007) further sup-
port the idea that adipose tissue has a major 
immune function.
Adipose tissue macrophages come in dif-
ferent forms based on cell surface phenotype. 
Figure 2. Prototype pattern of disease for health risk reduction connected to metabolic syndrome. 
Environmental exposures elevating the risk of metabolic syndrome are on the far left. Diseases and condi-
tions with elevated risk associated with metabolic syndrome are on the far right. The first window on the 
left illustrates the opportunity to prevent initiation of metabolic syndrome by identifying and protecting 
against problematic environmental exposures that increase the risk of metabolic syndrome. The second 
window shows the opportunity to intervene in the metabolic syndrome pattern and reduce the risk for pro-
gression to associated diseases. Prompt intervention focused on the entire metabolic syndrome disease 
pattern may be more effective than treatment begun much later in life (as indicated by the diminishing 
triangle). Both the prevention and intervention strategies are important components of overall health risk 
reduction. The focus on patterns of disease deviates from the traditional single-disease approach.





































Figure 3. Early-life risk factors for metabolic syndrome: a timeline of human development from conception 
to 4 years of age. Abbreviations: GALT, gut-associated lymphoid tissue; MO, macrophage. Categories of 
different risk factors for metabolic syndrome are shown across the top. Below the timeline, windows of 
immune maturation are indicated that appear to be most relevant to environmental risk of metabolic syn-
drome. Combined, these factors and the critical windows are useful to further investigate the connection 
of an immune dysfunction–metabolic syndrome in early life. The dashed line indicates that immune matu-
ration may continue after birth. Information derived from Dietert and Zelikoff (2008), Dietert and Dietert 
(2010), and DeWitt and Dietert (2010). 
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Additionally, significant changes occur in adi-
pose tissue in conjunction with elevated risk of 
metabolic syndrome conditions. For example, 
in mice, these macrophage subpopulations 
have been termed M1 and M2. The M1 mac-
rophages tend to produce more tumor necro-
sis factor-α (TNF-α) and chemokine ligand 
2 (CCL2), whereas the M2 macrophages are 
associated with higher interleukin-10 (anti-
inflammatory) cytokine production (Fujisaka 
et al. 2009). The M1 and M2 ratio appears 
to be a significant factor in insulin sensitiv-
ity (Fujisaka et al. 2009). In adipose tissue, 
factors secreted by infiltrating macrophages 
appear to alter preadipocyte differentiation, 
producing a proinflammatory and fibrotic 
environment that appears to be critical in the 
maintenance and progression of fat mass in 
obesity (Keophiphath et al. 2009).
Several events that are altered in early child-
hood have been associated with elevated risk of 
metabolic syndrome. For example, children 
who mature early (measured by growth param-
eters) reportedly have a higher risk of young 
adult metabolic syndrome than do those who 
mature later (Sun and Schubert 2009). These 
associations may reflect changes in hormone 
levels that may affect both body mass index 
and timing of pubescence. Additionally, a dis-
tinct inflammatory profile underlies obesity-
related metabolic disorders (Wisse 2004), and 
a marker of pediatric low-grade inflammation 
(white blood cell count) has been suggested 
as a possible marker for metabolic syndrome 
based on recent reports (Lee et al. 2010).
Immune-inflammatory dysfunction is also 
seen with prenatal exposures to environmen-
tal risk factors that produce postnatal lipid 
dysregulation. Zelikoff and colleagues demon-
strated that both are postnatal outcomes after 
in utero exposure of mice to cigarette smoke. 
Prenatal exposure to cigarette smoke caused 
suppression of cytotoxic T-lymphocyte func-
tion while also promoting transplanted tumor 
growth in male offspring (Ng et al. 2006). 
Cigarette smoke exposure in early life also 
altered immune homeostasis in offspring (Ng 
et al. 2008). Similar prenatal exposures to cig-
arette smoke produced alterations in blood lip-
ids and weight gain in the offspring (Ng et al. 
2009). In this latter study, the fat composition 
of the postnatal diet exerted an influence on 
the pattern of metabolic effects seen among 
male or female offspring.
Odegaard et al. (2007) reported that mac-
rophage polarization, including overproduction 
of CCL2 by macrophages in adipose tissues, 
is associated with the insulin resistance com-
ponent of metabolic syndrome. Interestingly, 
psoriasis cases are reported to have a higher level 
of proinflammatory cytokines than normal 
and are comorbid with both lipid abnormali-
ties and metabolic syndrome (Channual et al. 
2009; Gottlieb et al. 2008). This particular 
skin disorder may be associated with elevated 
production of TNF-α. Additionally, reduced 
numbers and function of T-regulatory cell pop-
ulations (CD4+Foxp3+) occurred concomitantly 
with insulin resistance (Feuerer et al. 2009). 
The underlying basis of the connection between 
inflammatory dysfunction and metabolic syn-
drome warrants additional investigation.
Applying the metabolic syndrome  example 
as a general approach. The significance of 
using the metabolic syndrome pattern to 
address environmental health risks is that, 
rather than focusing solely on factors related 
to stroke versus diabetes versus heart disease, 
there is an opportunity to design prevention 
and intervention strategies that can affect not 
just one disease but an entire associated pat-
tern of chronic conditions. When considering 
metabolic syndrome, the immune dysfunction 
component may be causative or simply an 
associated or disease-facilitating characteris-
tic. Future research will help to address this 
question. However, for other patterns of envi-
ronmentally influenced disease, the role of 
immune dysfunction is clear. In the following 
examples of “patterns,” the entryway condition 
or disease is clearly tied to early-life environ-
ment, DIT, and pediatric immune dysfunc-
tion. A “pattern” approach has already proved 
integral to the use of metabolic syndrome as 
a focal point for reducing the risk of cardio-
vascular disease, diabetes, and stoke. Similar 
benefits should be obtained by applying a 
similar “pattern” approach to other entryway 
diseases and conditions, including those that 
are based on underlying immune dysfunction.
Using Immune Dysfunction-
Based Patterns of Disease
The identification of prototypical immune-
based patterns of disease emerged in a recent 
sequence of publications (Dietert and Zelikoff 
2009, 2010). The authors compared the 
reported risk associations among 28 diseases 
and conditions where the entryway disease 
was prominent in childhood and where early-
life environmental risk factors were thought 
to be related to the induction of the disease 
(Dietert and Zelikoff 2010). In many cases 
of cohorts with the primary immune-related 
conditions, the secondary diseases did not 
arise until adulthood. Although some disease 
comorbidities were expected (e.g., the atopic 
triad of childhood asthma, allergic rhinitis, and 
atopic dermatitis), others were far less obvious 
(i.e., various cancers, cardiovascular diseases, 
neurobehavioral diseases, metabolic disorders, 
sleep disorders).
Categorizing patterns of immune-based 
disease. Four categories of immune-based pat-
terns of disease were previously defined based 
on the nature of the pediatric entryway disease 
(i.e., allergic diseases, autoimmune diseases, 
inflammatory diseases, and recurrent infectious 
diseases) (Dietert and Zelikoff 2010). Given 
information presented here, it seems likely that 
designation of a fifth category, “metabolic dis-
eases,” would be appropriate. It is important 
to note that secondary diseases and conditions 
within a given pattern were not in any way 
restricted to the category of the initial disease. 
Thus, pediatric allergic disease could give rise to 
an elevated risk of certain autoimmune, inflam-
matory, cancerous, and behavioral conditions. 
Likewise, certain recurrent pediatric infections 
were associated with an elevated risk of specific 
allergic, autoimmune, and inflammatory dis-
eases (Dietert and Zelikoff 2010).
There are at least two ways in which these 
patterns of disease with environmental influ-
ences can be used for health risk reduction: 
to better map the routes to specific diseases 
whose elevated risks are found in multiple 
immune-related patterns, and to serve as the 
basis for environmental protection and thera-
peutic strategies focused on multiple intercon-
nected diseases rather than single diseases in 
isolation. These two applications are illustrated 
in the following sections.
Using Patterns of Immune-
Based Disease for Improved 
Health Risk Reduction
To consider the utility of patterns of immune-
dysfunction–based disease for reducing 
environmental health risks, any number of 
entryway diseases could have been selected 
from our initial analysis (Dietert and Zelikoff 
2010). For example, celiac disease presents 
an interesting pattern because the entryway 
disease has both allergic and autoimmune 
components. However, for the present discus-
sion, we focused on a set of examples where 
entryway diseases represent different catego-
ries of immune-based diseases (allergy, auto-
immunity, inflammatory, infectious) and are 
focused in different specialized tissues (lung, 
skin, brain, gastrointestinal tract, pancreas).
Figure 4 depicts a Venn diagram of six such 
immune-based disease patterns. This shows the 
individual patterns. But, more importantly, it 
shows the intersection of different patterns and 
the sharing of increased risk for an individual 
disease by more than one pattern. The six pat-
terns are derived from information presented in 
Dietert and Zelikoff (2009). In Figure 4, entry-
way diseases are designated in bold type within 
each pattern. For each entryway disease, there 
are prenatal and childhood environmental risk 
factors that are thought to play a major role in 
disease development. Among the population 
diagnosed with the entryway disease, elevated 
risk of secondary diseases is indicated within 
each pattern.
The patterns diagrammed in Figure 4 pro-
vide several take-home messages, some that 
reinforce prior observations, and some that 
open up new opportunities for investigation. 
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Entryway diseases are each connected to sev-
eral other chronic diseases via elevated risk. 
Specific underlying immune dysfunction is 
likely to drive the comorbidities. In Figure 4, 
several routes appear to result in an increased 
risk of childhood asthma, with allergic, infec-
tious, and inflammatory components all being 
important. Depression, sleep, sensory, and 
psychological disorders are prominent in envi-
ronmentally influenced immune diseases, and 
the first three conditions cluster among vari-
ous autoimmune and inflammatory disease 
patterns. Earlier-life, immune-based diseases 
focused in specific tissues (e.g., lung, gastro-
intestinal tract, skin) are invariably associated 
with an elevated risk of later-life cancer in 
that tissue (Dietert, in press).
Figure 5 depicts the pattern for childhood 
asthma as an entryway disease using a flow 
chart for enhanced environmental health risk 
reduction. The diagram illustrates the connec-
tion between environmental risk factors and 
the complete spectrum of potential health risks. 
Elevated health risks are either well established 
or strongly suggested (Dietert and Zelikoff 
2009, 2010). When the scope of elevated 
health risks associated with childhood asthma 
are viewed beyond the single disease, the focus 
on effective prevention and management of 
childhood asthma is affected as well.
Prevention of Immune Insult 
and Entryway Diseases: Scope 
and Limitations
For those patterns of disease with immune 
involvement, preventing the underlying 
immune dysfunction is the single most effec-
tive option to minimize the risk of one or 
more chronic diseases later in life. Effectively 
managing the developing immune system 
includes not only the identification and avoid-
ance of environmental hazards such as immu-
notoxic chemicals and drugs, but also the 
optimization of maternal and pediatric diets 
and reduction of infectious agent triggers of 
immune-based disease. At the individual level, 
genetic background and epigenetic effects can 
also be useful considerations.
Because pediatric immune dysfunction can 
take many different forms, a focus on safety 
testing that relies primarily on adult exposure 
data and directed toward immunosuppression 
or allergenicity of a test chemical itself is lim-
ited, if not misdirected. A disconnect between 
testing goals and actual DIT-induced health 
risks was discussed in both a recent review 
(Dietert 2009b) and a subsequent forum on 
the topic (Spivey 2009). Many of the entry-
way diseases of concern today are linked with 
exaggerated, inappropriate, or misdirected 
immune and inflammatory responses and are 
likely to involve disruption of immune matu-
ration during early life. There are several seri-
ous implications of this dysfunction–disease 
connection. Continued reliance on immune 
safety assessment using adult exposures to 
accurately predict risk of asthma and type 1 
diabetes in children is inappropriate. For this 
reason, DIT testing should be required for the 
safety assessment of chemicals and drugs, and 
the evaluation performed should be directly 
relevant to the human immune-based dis-
eases of greatest environmental health concern 
(Dietert 2009b).
Figure 4. Venn diagram showing six patterns of immune-related diseases and the interactions among the 
patterns. Designated entryway diseases are shown in bold type within each pattern. Reported comorbid 
diseases or conditions are included for each pattern and those shared among multiple patterns fall within 
















































Figure 5. Strategies for breaking a pattern of immune-dysfunction–based disease using childhood asthma 
as the entryway condition. Diseases and conditions with reported elevated risk among asthmatics are 
shown on the far right. The first window on the left illustrates the opportunity to prevent the initiation of 
this disease pattern by blocking DIT-induced immune dysfunction and elevated risk of childhood asthma. 
The second window shows the opportunity to intervene in the pattern and reduce the risk for progression 
to associated diseases beyond childhood asthma. Prompt intervention focused on this pattern may be 
more effective than treatments that are begun just before the onset of additional diseases. The importance 
of timing of appropriate intervention for likelihood of success in breaking the pattern is depicted using a 
diminishing triangle. Both the prevention and intervention strategies are important components of overall 
health risk reduction. Data from Dietert and Zelikoff (2008, 2010).
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Effective prevention of patterns of disease 
involves implementation of effective strategies 
to identify environmental risk factors dur-
ing critical windows of early life and to more 
effectively protect vulnerable populations 
from priority risks. In the present review, the 
focus is on critical windows of immune vul-
nerability and exposures to environmental 
risk factors that elevate the chance of pediatric 
immune dysfunction. The importance of the 
first topic, risk of DIT, cannot be emphasized 
enough. If potentially problematic exposures 
to environmental risk factors that contribute 
to pediatric immune dysfunction and entry-
way diseases remain unknown, the disease 
pattern is likely to be initiated, or alterna-
tively, the immune system may be primed for 
heightened environmental sensitivity in later 
life. Once these early immune insults have 
occurred, the relative effectiveness of inter-
vention strategies may be lessened, and the 
comparative cost may be increased. Therefore, 
knowledge of the risk factors producing DIT 
is critical for making informed decisions for 
health risk reduction.
At present, the risk factors for pediatric 
immune dysfunction have not been com-
prehensively identified. This is not surpris-
ing given that DIT testing is not required 
at present (Dietert 2009b; Spivey 2009). 
Additionally, even when DIT testing may be 
performed, the parameters measured can lack 
relevance for allergic, autoimmune, inflam-
matory, and metabolic immune-based dis-
ease. Clearly confidence in the extent to which 
risk factors have been identified influences 
the quality of the decisions made. Improved 
knowledge of immune risk factors will result 
in fewer data gaps in risk reduction policies 
and, therefore, more effective and refined 
strategies for protecting children against entry-
way diseases. Obviously, not every risk factor 
for the developing immune system contributes 
to the same extent toward entryway diseases. 
Additionally, some risk factors for immune 
dysfunction are more easily avoided than are 
others. For this reason, priorities can be set to 
address the greatest risks as well as those most 
easily avoided when it comes to protecting 
pregnant women and children from exposure.
Intervention to Disrupt Disease 
Patterns: Scope and Limitations
Acceptance of the existence of patterns of 
immune-based disease has inherent rami-
fications. Among these is the concomitant 
recognition that, even within an individual, 
underlying immune dysfunction contributes 
to elevated risk for not one but several chronic 
diseases across a lifetime. For this reason, it 
is advantageous to be able to minimize the 
extent to which a specific pattern of disease 
can progress. A diagnosis of childhood asthma 
has certain implications for present medical 
care and health management. However, the 
management of pediatric asthma might be 
distinctly different if elevated risk of sleep 
disorders, lung cancer, obesity, recurrent 
respiratory infections, otitis media, behav-
ioral disorders, and olfactory dysfunction are 
added to the pediatrician’s concerns for a 
child’s health. For some of the comorbidities, 
risk reduction may occur with present man-
agement of entryway diseases. But for other 
comorbidities, special interventions may be 
needed to break the entryway disease pattern. 
This is more likely to occur if physicians are 
aware of the existence of disease patterns and 
the entryway disease or condition is treated 
with the health care goal of breaking the over-
all disease pattern rather than the potentially 
more restrictive goal of managing the symp-
toms of the initial presenting disease.
Problems arise when and if current man-
agement of childhood asthma, type 1 diabe-
tes, pediatric celiac disease, or recurrent otitis 
media deals only with the clinical symptoms 
but fails to address the underlying immune 
dysfunction that led to the entryway disease. 
The former treatment course would be more 
likely to leave intact the elevated risk of one 
or more additional diseases than would a 
pattern-based pediatric therapeutic approach 
(Dietert and Zelikoff 2009). This last point 
can be highlighted by the potential consid-
erations for managing type 1 diabetes in 
children. Treatments often focus on lifelong 
insulin administration, regulation of blood 
glucose levels, careful dietary controls, and 
effective exercise (Haller et al. 2005; Hood 
et al. 2009). But given that this population of 
children carries an elevated risk for additional 
autoimmune (autoimmune thyroiditis, celiac 
disease, multiple sclerosis) and inflammatory 
conditions (atherosclerosis, depression, sleep 
disorders) (Dietert and Zelikoff 2009), insu-
lin and glucose management alone is unlikely 
to correct underlying immune dysfunction. In 
contrast, therapies that include comprehensive 
immunomodulatory procedures (Zhao et al. 
2009) have the potential to correct the persis-
tent immune defect(s) and reduce the serious 
additional health risks.
As shown for patterns connected to met-
abolic syndrome (Figure 2) and childhood 
asthma (Figure 5), intervention can be used 
to disrupt a pattern of disease. In theory, this 
intervention could occur anytime after under-
lying immune dysfunction is identified. But 
in practice, this would occur after the diagno-
sis of the entryway disease (and detection of 
underlying immune dysfunction). A sliding 
scale is depicted in the intervention window 
after the onset and diagnosis of each entryway 
disease or condition. This is used to indicate 
that, across a lifetime, the most effective and 
comprehensive intervention opportunity to 
break a disease pattern and reduce the risk for 
all associated diseases is likely to be nearest to 
the time of entryway disease diagnosis (i.e., 
early in life). The longer underlying immune 
dysfunction persists as the individual ages, the 
more difficult it may be to reduce the risk for 
the entire spectrum of associated diseases.
For example, childhood asthma is often 
associated with other allergic conditions, and 
many of these can arise just before or after the 
appearance of asthma (Leynaert et al. 2000). 
Therefore, the window of intervention to 
effectively block the development of other 
comorbid allergic diseases in asthmatic chil-
dren may be quite narrow. Likewise, child-
hood asthma and obesity are often comorbid 
in young children (Tai et al. 2009). In con-
trast, lung cancer is most often diagnosed in 
older adults (Horner et al. 2009). The win-
dow of opportunity to intervene effectively 
and reduce the risk of lung cancer among 
asthmatic children is likely to be greater than 
for reducing the risk of other allergic condi-
tions or childhood obesity. However, even 
for adult-onset diseases such as lung cancer, 
as each decade of life passes with continuing 
immune dysfunction and mounting immune-
inflicted insult to the airways, effective inter-
vention is likely to be more difficult.
In general, a global medical approach that 
includes attention to any underlying immune 
dysfunction early in life, such as immediately 
after a pediatric entryway disease is diagnosed, 
should be useful. It is more likely to break an 
immune-based pattern of disease than sequen-
tial, condition-restricted medical treatment of 
each condition (resulting in polypharmacy) 
within a pattern.
Conclusions
Strategies to break patterns of environmentally 
influenced illnesses and diseases provide tools 
to reduce the risk of multiple diseases over 
a lifetime by using a more holistic preventa-
tive and therapeutic approach. Use of pat-
terns of environmentally influenced disease 
provides novel opportunities for prevention of 
pediatric- and adult-onset chronic disease, and 
an opportunity to disrupt patterns of disease 
through forward-looking therapeutic interven-
tions. As discussed in this review, immune 
dysfunction appears to be at the center of 
many patterns of disease, and the pivotal role 
of immune homeostasis in tissue and organs 
has probably been underappreciated relative to 
health risks across a lifetime.
Several recently defined patterns of dis-
ease that have been described in this review 
illustrate how both individual patterns of 
immune-related disease as well as intersec-
tions of multiple disease patterns can be used 
for reduction of environmental health risks. 
Although this type of holistic approach to 
environmental health risk reduction appears 
promising, it would require several changes 
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away from more traditional approaches. For 
example, evidence of immunotoxicity after 
adult exposure should not be a prerequisite 
for developmental immune safety testing. 
Instead, DIT testing should be required in 
the safety assessment of chemicals and drugs 
and should use end points of direct relevance 
to the most significant immune-based human 
diseases. Additionally, therapeutic approaches 
toward entryway diseases of a pattern should 
consider the totality of health risks within 
the pattern rather than focusing solely on the 
immediate clinical symptoms.
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